Connect Biopharma Achieves 200–400 mL FEV1 Gains and Secures $20.2M Financing
Connect Biopharma’s Phase 1 IV study of rademikibart in asthma and COPD patients showed mean FEV1 gains of 200–400 mL maintained through Day 29 with rapid 200 mL improvements within 15 minutes. The company raised $20.2 million at $3.25 per share, lifting cash to $44.3 million and securing runway into H2 2027.
1. Clinical Phase 1 IV Study Results
In March 2026, positive topline data from a Phase 1 intravenous rademikibart study in stable asthma and COPD patients demonstrated mean FEV1 improvements of approximately 200–400 mL maintained through Day 29 after a single 300 mg IV push, with rapid gains of ≥200 mL within 15 minutes and a favorable safety profile.
2. Phase 3 Atopic Dermatitis Data
Rademikibart achieved rapid, durable efficacy across all key endpoints through 52 weeks in moderate-to-severe atopic dermatitis patients, with near-maximal responses in ~90% of subjects, safety comparable to placebo at 16 weeks, and lower conjunctivitis rates versus competing class agents.
3. Ongoing Phase 2 Seabreeze STAT Trials
Recruitment is ongoing for the Seabreeze STAT studies evaluating rademikibart as adjunctive treatment for acute exacerbations in asthma and COPD, with topline safety and efficacy data expected in mid-2026 to inform potential acute use.
4. Financial and Corporate Update
The company completed a $20.2 million private placement at $3.25 per share, boosting cash, cash equivalents and short-term investments to $44.3 million as of December 31, 2025, and extending its cash runway into the second half of 2027 under current operating plans.